CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands to Gain Substantial Revenue Through Licensing of DehydraTECH(TM)

Company: Lexaria Bioscience Corp. (LEXX)
Category: Stock Spotlights

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced that Japanese Licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand, “Ko.” “The exclusive rights between Premier and Lexaria are subject to two previously issued licenses for using DehydraTECH technology in Japan for non-pharmaceutical cannabinoid products… Under the terms of the license agreement with Lexaria, Premier purchased rights to the company’s DehydraTECH technology for use in the non-pharmaceutical market for CBD and hemp ingredients in oral liquid and non-liquid product form, including topical, hair care, lip care, and cosmetics,” a recent article reads. “Lexaria stands to gain substantial revenue through the licensing of DehydraTECH technology across minimum quarterly payments for use by Premier and royalties for products sold… To retain ongoing exclusivity, the minimum quarterly payments from Premier to Lexaria will begin Sept. 1, 2022, and will total US$4,527,500 during the first five years of the agreement. Additional payment beyond five years will be required to keep the license in good standing.”

To view the full article, visit https://cnw.fm/gNG7N

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 26 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722